MA50435A - Anticorps anti-ligand anti-cd40 thérapeutiques - Google Patents

Anticorps anti-ligand anti-cd40 thérapeutiques

Info

Publication number
MA50435A
MA50435A MA050435A MA50435A MA50435A MA 50435 A MA50435 A MA 50435A MA 050435 A MA050435 A MA 050435A MA 50435 A MA50435 A MA 50435A MA 50435 A MA50435 A MA 50435A
Authority
MA
Morocco
Prior art keywords
antibodies
ligand
therapeutic
therapeutic anti
ligand anti
Prior art date
Application number
MA050435A
Other languages
English (en)
Inventor
Alexey Lugovskoy
Original Assignee
Als Therapy Development Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Als Therapy Development Inst filed Critical Als Therapy Development Inst
Publication of MA50435A publication Critical patent/MA50435A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA050435A 2017-05-24 2018-05-23 Anticorps anti-ligand anti-cd40 thérapeutiques MA50435A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762510471P 2017-05-24 2017-05-24

Publications (1)

Publication Number Publication Date
MA50435A true MA50435A (fr) 2020-09-02

Family

ID=63592816

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050435A MA50435A (fr) 2017-05-24 2018-05-23 Anticorps anti-ligand anti-cd40 thérapeutiques

Country Status (14)

Country Link
US (2) US11384152B2 (fr)
EP (1) EP3630843A2 (fr)
JP (2) JP7766392B2 (fr)
KR (1) KR102840867B1 (fr)
CN (2) CN110662768B (fr)
AU (2) AU2018271915B2 (fr)
CA (1) CA3063730A1 (fr)
GB (1) GB2578037A (fr)
IL (3) IL322942A (fr)
MA (1) MA50435A (fr)
MX (1) MX2023004314A (fr)
RU (2) RU2022108410A (fr)
SG (1) SG10202111207TA (fr)
WO (1) WO2018217918A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
MA50435A (fr) * 2017-05-24 2020-09-02 Als Therapy Development Inst Anticorps anti-ligand anti-cd40 thérapeutiques
JP7775080B2 (ja) * 2019-07-01 2025-11-25 トニックス ファーマ リミテッド 抗ｃｄ１５４抗体およびその使用
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
WO2023230538A2 (fr) * 2022-05-27 2023-11-30 Eledon Pharmaceuticals, Inc. Méthodes pour le traitement de la sclérose latérale amyotrophique
EP4688856A1 (fr) 2023-04-03 2026-02-11 Regeneron Pharmaceuticals, Inc. Méthodes pour améliorer la survie d'une greffe à l'aide d'anticorps à chaîne gamma du récepteur il-2
WO2025117849A1 (fr) 2023-11-28 2025-06-05 Eledon Pharmaceuticals, Inc. Méthodes et compositions pour la prévention du rejet de greffe
WO2025235683A1 (fr) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Procédés et compositions pour la prévention du rejet de greffe
WO2025235670A1 (fr) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Utilisation d'anticorps anti-ligand cd40 pour l'immunosuppression dans une transplantation de cellules d'îlots
CN119823269B (zh) * 2024-12-10 2025-11-07 上海交通大学医学院附属瑞金医院 Cd40配体的抗原表位肽、抗体及应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
CA2089229C (fr) 1992-02-14 2010-04-13 Alejandro A. Aruffo Recepteur cd40cr et ligands pour celui-ci
WO1995006481A1 (fr) 1993-09-02 1995-03-09 Trustees Of Dartmouth College Procedes permettant d'induire la tolerance des cellules t a specificite antigenique
US5833987A (en) 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
NZ337072A (en) 1997-01-10 2000-12-22 Biogen Inc use of an anti-CD40L compounds to inhibit the progression of nephritis, stabilize nephritis or reverse nephritis in a patient with an immune complex disease
WO1998052606A1 (fr) 1997-05-17 1998-11-26 Biogen, Inc. Utilisation d'un interrupteur de fixation cd40:cd154 pour prevenir les reponses immunitaires indesirables, en particulier le rejet de greffe
KR20010072564A (ko) 1998-04-03 2001-07-31 존 에프. 카바나프 루푸스 및 관련된 신장 질환의 치료 및/또는 반전에사용되는 안티 ｇｐ39 항체의 용도
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
WO2001034194A1 (fr) 1999-11-08 2001-05-17 Idec Pharmaceuticals Corporation Traitement de tumeurs malignes des cellules b a l'aide d'anticorps anti-cd40l associes a des anticorps anti-cd20, et/ou chimiotherapie et radiotherapie
CN100490895C (zh) 2000-02-01 2009-05-27 泛遗传学公司 结合cd40的apc激活分子
GB0006398D0 (en) 2000-03-16 2000-05-03 Novartis Ag Organic compounds
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
BR0110779A (pt) 2000-05-12 2005-01-11 Beth Israel Hospital Composições e métodos para adquirir supressão imunológica
AU6461201A (en) 2000-07-12 2002-01-21 Idec Pharma Corp Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
AU8867501A (en) 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
WO2002018540A2 (fr) 2000-09-01 2002-03-07 Biogen, Inc. Nouveaux composes interrompant la fixation de cd40 et de cd154 et leur utilisation pour traiter des complications immunologiques
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
AU2003284968A1 (en) 2002-10-25 2004-05-13 University Of South Florida Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
KR20120090094A (ko) 2003-06-13 2012-08-16 바이오겐 아이덱 엠에이 인코포레이티드 아글리코실 항-ｃｄ154(ｃｄ40 리간드) 항체 및 이의 용도
JP2007527703A (ja) 2003-07-08 2007-10-04 ジェネスト アー／エス 肺炎球菌表面付着因子Ａタンパク質（ＰｓａＡ）に関する結合メンバー
NZ580688A (en) 2003-07-26 2012-03-30 Biogen Idec Inc Method of designing altered antibodies having improved antigen-binding affinity
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
US20170166655A1 (en) 2004-03-26 2017-06-15 Xencor, Inc. Novel immunoglobulin variants
EP2399936A3 (fr) 2004-07-26 2012-02-22 Biogen Idec MA Inc. Anticorps anti-CD154
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
TWI309240B (en) * 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
WO2006138316A2 (fr) 2005-06-14 2006-12-28 Biogen Idec Ma Inc. Methodes permettant d'administrer des molecules au systeme nerveux central
JP5396083B2 (ja) 2005-11-17 2014-01-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血小板凝集アッセイ
TW200738261A (en) 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
US7647438B1 (en) 2006-05-09 2010-01-12 Integrated Device Technology, Inc. Binary base address sorting method and device with shift vector
WO2008140603A2 (fr) 2006-12-08 2008-11-20 Macrogenics, Inc. MÉTHODES POUR LE TRAITEMENT DE MALADIE AU MOYEN D'IMMUNOGLOBULINES COMPRENANT DES RÉGIONS FC QUI PRÉSENTENT DES AFFINITÉS ALTÉRÉES POUR FCγR D'ACTIVATION ET FCγR D'INHIBITION
EP2125894B1 (fr) 2007-03-22 2018-12-19 Biogen MA Inc. Protéines de liaison, incluant des anticorps, dérivés d'anticorps et fragments d'anticorps, qui se lient spécifiquement à cd154 et leurs utilisations
KR20100021601A (ko) 2007-05-14 2010-02-25 바이오겐 아이덱 엠에이 인코포레이티드 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
MX2011000616A (es) * 2008-07-17 2011-02-24 Novartis Ag Composiciones y metodos de uso para anticuerpos terapeuticos.
GB0815788D0 (en) * 2008-08-29 2008-10-08 Isis Innovation Therapeutic antibodies
ES2650267T3 (es) 2008-12-05 2018-01-17 Als Therapy Development Institute Método para el tratamiento de enfermedades neurodegenerativas
US9044459B2 (en) 2008-12-05 2015-06-02 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
WO2010085682A2 (fr) 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Polypeptides fc stabilisés avec une fonction effectrice réduite et procédés d'utilisation
JP2013543384A (ja) * 2010-10-05 2013-12-05 ノバルティス アーゲー 抗−ｉｌ１２ｒベータ１抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
WO2012103218A1 (fr) 2011-01-25 2012-08-02 University Of South Florida Modèle transgénique de la maladie d'alzheimer
BR112013024574B1 (pt) 2011-03-29 2022-08-09 Roche Glycart Ag Anticorpo e uso do anticorpo
US9028826B2 (en) 2011-04-04 2015-05-12 The Trustees Of Dartmouth College Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
CA2832281C (fr) * 2011-04-04 2019-11-05 Trustees Of Dartmouth College Anticorps anti-cd154 ayant une liaison deterioree au fcr et/ou des proprietes de liaison au complement deterioree et leur utilisation dans des therapies immunologiques
AR086360A1 (es) 2011-04-21 2013-12-11 Bristol Myers Squibb Co Polipeptidos anticuerpos que antagonizan cd40
MX2014002289A (es) 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Anticuerpos fc especificos en tandem.
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
KR102133060B1 (ko) 2012-05-11 2020-07-10 메디뮨 리미티드 Ｃｔｌａ－４ 변이체
CN105121621B (zh) 2012-10-18 2019-08-02 张永新 用于细胞动静态交替培养的生物反应器系统及其方法
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
EA201691634A1 (ru) * 2014-03-19 2016-11-30 Бристол-Маерс Сквибб Компани Способы лечения отторжения трансплантата с использованием доменного антитела, направленного против cd40l
US20170042972A1 (en) 2014-04-25 2017-02-16 Chetan KARYEKAR Use of ctla4 compound for achieving drug-free remission in subjects with early ra
US20170233485A1 (en) 2014-08-18 2017-08-17 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
MA41459A (fr) * 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
MA50435A (fr) * 2017-05-24 2020-09-02 Als Therapy Development Inst Anticorps anti-ligand anti-cd40 thérapeutiques

Also Published As

Publication number Publication date
IL270729B1 (en) 2025-10-01
US20230048260A1 (en) 2023-02-16
RU2022108410A (ru) 2022-04-05
MX2023004314A (es) 2023-05-04
IL270729B2 (en) 2026-02-01
JP7766392B2 (ja) 2025-11-10
WO2018217918A2 (fr) 2018-11-29
RU2019143098A3 (fr) 2021-09-20
IL270729A (en) 2020-01-30
SG10202111207TA (en) 2021-11-29
IL309444A (en) 2024-02-01
CN110662768B (zh) 2024-01-30
AU2025204772A1 (en) 2025-07-17
IL309444B2 (en) 2026-02-01
AU2018271915A1 (en) 2019-11-28
CN110662768A (zh) 2020-01-07
EP3630843A2 (fr) 2020-04-08
CN117843789A (zh) 2024-04-09
KR102840867B1 (ko) 2025-07-30
JP2023065390A (ja) 2023-05-12
WO2018217918A3 (fr) 2019-01-17
US20200223932A1 (en) 2020-07-16
GB201918703D0 (en) 2020-01-29
US11384152B2 (en) 2022-07-12
JP2020521745A (ja) 2020-07-27
IL309444B1 (en) 2025-10-01
CA3063730A1 (fr) 2018-11-29
RU2770209C2 (ru) 2022-04-14
IL322942A (en) 2025-10-01
GB2578037A (en) 2020-04-15
AU2018271915B2 (en) 2025-03-27
KR20200010294A (ko) 2020-01-30
RU2019143098A (ru) 2021-06-24

Similar Documents

Publication Publication Date Title
MA52884A (fr) Anticorps anti-il-11
MA53434A (fr) Anticorps anti-tigit
FR25C1022I1 (fr) Anticorps anti-pd-1
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA47268A (fr) Anticorps anti-gpc3
EP3498840A4 (fr) Anticorps anti-lag-3
MA50435A (fr) Anticorps anti-ligand anti-cd40 thérapeutiques
EP3423089A4 (fr) Anticorps anti-tigit
IL272349A (en) Anti-cd137 antibodies
EP3883970A4 (fr) Anticorps anti-b7-h3
EP3334757A4 (fr) Anticorps anti-tigit
EP3387442A4 (fr) Anticorps anti-cd73 humanisés
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
EP3297671A4 (fr) Anticorps anti-ror1
EP3334824A4 (fr) Anticorps anti-pd-1
MA46272A (fr) Anticorps anti-cd27
EP3492591A4 (fr) Anticorps anti-b7-h4
EP3383915A4 (fr) Anticorps anti-pd-1
EP3526247A4 (fr) Anticorps anti-il1-rap
EP3617231A4 (fr) Anticorps anti-gpc-1
EP3399992A4 (fr) Anticorps autoréticulants
EP3484919A4 (fr) Anticorps anti-bêta-amyloïde
MA51134A (fr) Anticorps anti-alpha-synucléine
EP3526251A4 (fr) Anticorps anti-p53